- Home
- RANI vs HHS Comparison
RANI vs HHS Comparison
Compare RANI & HHS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RANI
- HHS
- Stock Information
- Founded
- RANI 2012
- HHS 1923
- Country
- RANI United States
- HHS United States
- Employees
- RANI N/A
- HHS N/A
- Industry
- RANI Medicinal Chemicals and Botanical Products
- HHS Advertising
- Sector
- RANI Health Care
- HHS Consumer Discretionary
- Exchange
- RANI Nasdaq
- HHS Nasdaq
- Market Cap
- RANI 24.2M
- HHS 26.9M
- IPO Year
- RANI 2021
- HHS N/A
- Fundamental
- Price
- RANI $1.90
- HHS $2.77
- Analyst Decision
- RANI Strong Buy
- HHS
- Analyst Count
- RANI 6
- HHS 0
- Target Price
- RANI $8.67
- HHS N/A
- AVG Volume (30 Days)
- RANI 21.6M
- HHS 300.5K
- Earning Date
- RANI 11-06-2025
- HHS 11-10-2025
- Dividend Yield
- RANI N/A
- HHS N/A
- EPS Growth
- RANI N/A
- HHS N/A
- EPS
- RANI N/A
- HHS N/A
- Revenue
- RANI $1,200,000.00
- HHS $166,841,000.00
- Revenue This Year
- RANI N/A
- HHS $6.54
- Revenue Next Year
- RANI N/A
- HHS N/A
- P/E Ratio
- RANI N/A
- HHS N/A
- Revenue Growth
- RANI N/A
- HHS N/A
- 52 Week Low
- RANI $0.39
- HHS $2.33
- 52 Week High
- RANI $3.87
- HHS $6.69
- Technical
- Relative Strength Index (RSI)
- RANI 54.20
- HHS 37.20
- Support Level
- RANI $1.77
- HHS $2.33
- Resistance Level
- RANI $2.16
- HHS $2.99
- Average True Range (ATR)
- RANI 0.35
- HHS 0.17
- MACD
- RANI -0.07
- HHS -0.00
- Stochastic Oscillator
- RANI 41.74
- HHS 38.60
About RANI Rani Therapeutics Holdings Inc.
Rani Therapeutics Holdings Inc is a clinical-stage biotherapeutics company advancing technologies to enable the development of orally administered biologics to provide patients, physicians, and healthcare systems with a convenient alternative to painful injections. The company has developed the RaniPill capsule, which is designed to deliver a wide variety of drug substances, including antibodies, proteins, peptides, and oligonucleotides. RaniPill is a proprietary and patented platform technology, intended to replace subcutaneous or IV injection of biologics with oral dosing. The company is also engaged in developing RaniPill HC, which is intended to enable the delivery of drug payloads in liquid form with high bioavailability.
About HHS Harte-Hanks Inc.
Harte-Hanks Inc is a customer experience company. The Company operates three business segments: Marketing Services; Customer Care; and Fulfillment & Logistics Services. The company has a geographic presence in the United States and Other countries. The majority of the revenue is earned from the United States.